Nutrition Business Journal

23andMes Next Act

Company repositions its genetic database as tool for developing new drugs

Find out what your DNA says about your family.” That’s what’s listed on the 23andMe homepage, but when the startup first launched it was framed differently. Then, 23andMe offered testing for more than 200 traits, helping customers learn if they were genetically predisposed to breast cancer, Alzheimer’s, Huntington’s, and other diseases. Medical claims like these brought FDA scrutiny in 2013, and the company was forced to back off. Now, in its lat

All access premium subscription

This content requires a subscription to Nutrition Business Journal.

As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.

Email [email protected] for more information about subscribing.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.